Therefore, the development of Hsp90 isoform-selective inhibitors represents a new paradigm for cancer treatment and provides a mechanism by which isoform-dependent substrates can be elucidated and then selectively targeted for degradation. This evidence concerns the gene HSP90AA1 and cancer.